Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
52.94 USD | -0.66% | -11.75% | +92.51% |
03/06 | Merus Says Target Tumors in Lung Cancer Patients Decrease in Size After MCLA-129 Treatment | MT |
03/06 | Truist Securities Raises Price Target on Merus to $88 From $69, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+92.51% | 3.51B | |
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+1.31% | 22.48B | |
-9.74% | 18.32B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B |
- Stock Market
- Equities
- MRUS Stock
- News Merus N.V.
- Merus Says US FDA Grants Breakthrough Therapy Designation for Zencutuzumab for Lung Cancer